Regeneron Pharmaceuticals
A New Era Begins! Intellia Reports First Clinical Proof for Direct CRISPR Genome Editing in Humans
2021-06-27
Monoclonal Antibodies for COVID-19: AstraZeneca and Regeneron’s Therapies Endure Contrasting Fortunes
2021-06-16
Eli Lilly’s Antibody Cocktail Shines in Phase 3 Study, Significantly Reduces COVID-19 Deaths
2021-03-11
FDA Okay of Regeneron’s PD-1 Inhibitor Marks Entry of First Immunotherapy for Advanced Basal Cell Carcinoma
2021-02-12
Key Takeaways from the JPM Healthcare Conference: Gilead, Regeneron Lay Oncology Plans, Merck Looks Beyond Keytruda
2021-01-17
A 11-Year-Old, Survivor-Derived Antibody Becomes Second Ebola Therapy to Bag FDA Approval
2020-12-23
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115